X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs NATCO PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB NATCO PHARMA DR. REDDYS LAB/
NATCO PHARMA
 
P/E (TTM) x 29.1 16.0 181.9% View Chart
P/BV x 3.1 17.2 18.1% View Chart
Dividend Yield % 0.8 0.7 127.4%  

Financials

 DR. REDDYS LAB   NATCO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
NATCO PHARMA
Mar-14
DR. REDDYS LAB/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788877 317.9%   
Low Rs1,902424 449.0%   
Sales per share (Unadj.) Rs860.8223.4 385.2%  
Earnings per share (Unadj.) Rs57.131.1 183.7%  
Cash flow per share (Unadj.) Rs122.040.3 302.9%  
Dividends per share (Unadj.) Rs20.005.00 400.0%  
Dividend yield (eoy) %0.90.8 110.9%  
Book value per share (Unadj.) Rs757.7219.5 345.2%  
Shares outstanding (eoy) m165.9133.07 501.7%   
Bonus/Rights/Conversions ESOPPA-  
Price / Sales ratio x2.72.9 93.6%   
Avg P/E ratio x41.120.9 196.3%  
P/CF ratio (eoy) x19.216.1 119.0%  
Price / Book Value ratio x3.13.0 104.5%  
Dividend payout %35.016.1 217.8%   
Avg Mkt Cap Rs m389,03421,504 1,809.1%   
No. of employees `00023.5NA-   
Total wages/salary Rs m32,1491,128 2,850.8%   
Avg. sales/employee Rs Th6,070.8NM-  
Avg. wages/employee Rs Th1,366.6NM-  
Avg. net profit/employee Rs Th402.5NM-  
INCOME DATA
Net Sales Rs m142,8107,389 1,932.8%  
Other income Rs m1,552167 928.8%   
Total revenues Rs m144,3627,556 1,910.6%   
Gross profit Rs m23,5121,793 1,311.1%  
Depreciation Rs m10,772304 3,538.8%   
Interest Rs m788366 215.2%   
Profit before tax Rs m13,5041,290 1,047.0%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380309 1,418.9%   
Profit after tax Rs m9,4681,027 921.5%  
Gross profit margin %16.524.3 67.8%  
Effective tax rate %32.423.9 135.5%   
Net profit margin %6.613.9 47.7%  
BALANCE SHEET DATA
Current assets Rs m104,9843,681 2,851.8%   
Current liabilities Rs m68,9383,123 2,207.6%   
Net working cap to sales %25.27.6 333.9%  
Current ratio x1.51.2 129.2%  
Inventory Days Days7489 83.1%  
Debtors Days Days10459 176.5%  
Net fixed assets Rs m104,3857,685 1,358.3%   
Share capital Rs m830331 251.0%   
"Free" reserves Rs m124,8866,670 1,872.4%   
Net worth Rs m125,7167,259 1,731.9%   
Long term debt Rs m25,089955 2,627.4%   
Total assets Rs m225,44311,957 1,885.4%  
Interest coverage x18.14.5 401.1%   
Debt to equity ratio x0.20.1 151.7%  
Sales to assets ratio x0.60.6 102.5%   
Return on assets %4.511.7 39.0%  
Return on equity %7.514.2 53.2%  
Return on capital %9.720.7 46.8%  
Exports to sales %039.4 0.0%   
Imports to sales %05.7 0.0%   
Exports (fob) Rs mNA2,908 0.0%   
Imports (cif) Rs mNA421 0.0%   
Fx inflow Rs m72,6233,445 2,107.8%   
Fx outflow Rs m18,916703 2,691.5%   
Net fx Rs m53,7072,743 1,958.3%   
CASH FLOW
From Operations Rs m18,0301,440 1,251.8%  
From Investments Rs m-14,883-1,089 1,366.4%  
From Financial Activity Rs m-4,440-353 1,258.9%  
Net Cashflow Rs m-1,236-1 82,953.0%  

Share Holding

Indian Promoters % 25.5 52.0 49.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 5.4 7.8 68.9%  
FIIs % 35.3 16.6 212.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 26.0 58.8%  
Shareholders   75,885 25,395 298.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  PFIZER  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 17, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS